Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.
Murali Dhar, T.G., Wrobleski, S.T., Lin, S., Furch, J.A., Nirschl, D.S., Fan, Y., Todderud, G., Pitt, S., Doweyko, A.M., Sack, J.S., Mathur, A., McKinnon, M., Barrish, J.C., Dodd, J.H., Schieven, G.L., Leftheris, K.(2007) Bioorg Med Chem Lett 17: 5019-5024
- PubMed: 17664068 
- DOI: https://doi.org/10.1016/j.bmcl.2007.07.029
- Primary Citation of Related Structures:  
2QD9 - PubMed Abstract: 
The synthesis and structure-activity relationships (SAR) of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds are described. This effort led to the identification of compound (21) as a potent inhibitor of p38alpha MAP kinase with good cellular potency toward the inhibition of TNF-alpha production. X-ray co-crystallography of an oxalamide analog (24) bound to unphosphorylated p38alpha is also disclosed.
Organizational Affiliation: 
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000, USA. [email protected]